Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM   3:59:52 PM EDT
11.09
+0.11 (+1.00%)
Products

Rhythm Pharmaceuticals Submits Supplemental NDA To U.S. FDA For IMCIVREE For Treatment Of Obesity In Bardet-Biedl And Alström Syndromes

Published: 09/20/2021 12:04 GMT
Rhythm Pharmaceuticals Inc. (RYTM) - Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for Imcivree® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-biedl and AlstrÖm Syndromes.